nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—TBK1—glaucoma	0.451	0.715	CbGaD
Crizotinib—NTRK1—glaucoma	0.179	0.285	CbGaD
Crizotinib—TIE1—endothelium—glaucoma	0.00174	0.0302	CbGeAlD
Crizotinib—RIPK2—endothelium—glaucoma	0.00143	0.0248	CbGeAlD
Crizotinib—NEK9—connective tissue—glaucoma	0.00142	0.0246	CbGeAlD
Crizotinib—PTK2—endothelium—glaucoma	0.00133	0.023	CbGeAlD
Crizotinib—SIK2—connective tissue—glaucoma	0.00128	0.0221	CbGeAlD
Crizotinib—EPHB4—endothelium—glaucoma	0.00121	0.021	CbGeAlD
Crizotinib—MAPK7—retina—glaucoma	0.00118	0.0205	CbGeAlD
Crizotinib—EPHA8—eye—glaucoma	0.00118	0.0205	CbGeAlD
Crizotinib—TEK—endothelium—glaucoma	0.00116	0.0201	CbGeAlD
Crizotinib—MAPK7—connective tissue—glaucoma	0.00115	0.0199	CbGeAlD
Crizotinib—MET—eye—glaucoma	0.00112	0.0194	CbGeAlD
Crizotinib—MET—retina—glaucoma	0.00111	0.0192	CbGeAlD
Crizotinib—MET—connective tissue—glaucoma	0.00108	0.0187	CbGeAlD
Crizotinib—CDK7—connective tissue—glaucoma	0.00104	0.0181	CbGeAlD
Crizotinib—ACVR1B—eye—glaucoma	0.00103	0.0179	CbGeAlD
Crizotinib—EPHA3—eye—glaucoma	0.00103	0.0179	CbGeAlD
Crizotinib—SRC—endothelium—glaucoma	0.00103	0.0178	CbGeAlD
Crizotinib—EPHA3—retina—glaucoma	0.00102	0.0177	CbGeAlD
Crizotinib—JAK3—connective tissue—glaucoma	0.000948	0.0165	CbGeAlD
Crizotinib—STK4—connective tissue—glaucoma	0.000931	0.0162	CbGeAlD
Crizotinib—EPHA5—eye—glaucoma	0.000913	0.0158	CbGeAlD
Crizotinib—EPHA5—retina—glaucoma	0.000905	0.0157	CbGeAlD
Crizotinib—MAP4K1—retina—glaucoma	0.000886	0.0154	CbGeAlD
Crizotinib—TYRO3—connective tissue—glaucoma	0.00088	0.0153	CbGeAlD
Crizotinib—ALK—connective tissue—glaucoma	0.00088	0.0153	CbGeAlD
Crizotinib—IGF1R—eye—glaucoma	0.000877	0.0152	CbGeAlD
Crizotinib—LYN—connective tissue—glaucoma	0.000875	0.0152	CbGeAlD
Crizotinib—STK3—eye—glaucoma	0.000853	0.0148	CbGeAlD
Crizotinib—IGF1R—connective tissue—glaucoma	0.000845	0.0147	CbGeAlD
Crizotinib—TESK1—eye—glaucoma	0.000825	0.0143	CbGeAlD
Crizotinib—MERTK—eye—glaucoma	0.000802	0.0139	CbGeAlD
Crizotinib—MERTK—retina—glaucoma	0.000795	0.0138	CbGeAlD
Crizotinib—TESK1—connective tissue—glaucoma	0.000795	0.0138	CbGeAlD
Crizotinib—MAP3K12—eye—glaucoma	0.000776	0.0135	CbGeAlD
Crizotinib—ACVR1—eye—glaucoma	0.000776	0.0135	CbGeAlD
Crizotinib—ACVR1—retina—glaucoma	0.000769	0.0134	CbGeAlD
Crizotinib—PTK2B—Pindolol—Levobunolol—glaucoma	0.000754	0.276	CbGdCrCtD
Crizotinib—PTK2B—Pindolol—Carteolol—glaucoma	0.000754	0.276	CbGdCrCtD
Crizotinib—ACVR1—connective tissue—glaucoma	0.000748	0.013	CbGeAlD
Crizotinib—FLT3—connective tissue—glaucoma	0.000748	0.013	CbGeAlD
Crizotinib—CYP3A5—Clonidine—glaucoma	0.000723	0.172	CbGbCtD
Crizotinib—PTK2B—Pindolol—Metipranolol—glaucoma	0.00072	0.263	CbGdCrCtD
Crizotinib—BMP2K—connective tissue—glaucoma	0.000705	0.0122	CbGeAlD
Crizotinib—RIPK2—eye—glaucoma	0.000701	0.0122	CbGeAlD
Crizotinib—RIPK2—retina—glaucoma	0.000695	0.0121	CbGeAlD
Crizotinib—PTK2B—connective tissue—glaucoma	0.000681	0.0118	CbGeAlD
Crizotinib—RIPK2—connective tissue—glaucoma	0.000676	0.0117	CbGeAlD
Crizotinib—TBK1—eye—glaucoma	0.000651	0.0113	CbGeAlD
Crizotinib—TYK2—eye—glaucoma	0.000647	0.0112	CbGeAlD
Crizotinib—TYK2—retina—glaucoma	0.000641	0.0111	CbGeAlD
Crizotinib—MAP3K2—connective tissue—glaucoma	0.00064	0.0111	CbGeAlD
Crizotinib—PTK2—connective tissue—glaucoma	0.000627	0.0109	CbGeAlD
Crizotinib—RPS6KB1—eye—glaucoma	0.000626	0.0109	CbGeAlD
Crizotinib—TYK2—connective tissue—glaucoma	0.000623	0.0108	CbGeAlD
Crizotinib—RPS6KB1—retina—glaucoma	0.000621	0.0108	CbGeAlD
Crizotinib—AXL—eye—glaucoma	0.00062	0.0108	CbGeAlD
Crizotinib—AXL—retina—glaucoma	0.000614	0.0107	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—glaucoma	0.000603	0.0105	CbGeAlD
Crizotinib—AXL—connective tissue—glaucoma	0.000597	0.0104	CbGeAlD
Crizotinib—CYP3A4—Pilocarpine—glaucoma	0.000578	0.138	CbGbCtD
Crizotinib—EPHB4—connective tissue—glaucoma	0.000571	0.00991	CbGeAlD
Crizotinib—JAK2—connective tissue—glaucoma	0.000567	0.00984	CbGeAlD
Crizotinib—ABCB1—Timolol—glaucoma	0.000554	0.132	CbGbCtD
Crizotinib—TEK—connective tissue—glaucoma	0.000546	0.00948	CbGeAlD
Crizotinib—YES1—eye—glaucoma	0.000524	0.00909	CbGeAlD
Crizotinib—YES1—retina—glaucoma	0.000519	0.00901	CbGeAlD
Crizotinib—TAOK3—eye—glaucoma	0.000517	0.00897	CbGeAlD
Crizotinib—TAOK3—retina—glaucoma	0.000512	0.00889	CbGeAlD
Crizotinib—YES1—connective tissue—glaucoma	0.000505	0.00876	CbGeAlD
Crizotinib—SRC—eye—glaucoma	0.000504	0.00874	CbGeAlD
Crizotinib—PTK2B—Pindolol—Betaxolol—glaucoma	0.000503	0.184	CbGdCrCtD
Crizotinib—SRC—retina—glaucoma	0.000499	0.00867	CbGeAlD
Crizotinib—TAOK3—connective tissue—glaucoma	0.000498	0.00865	CbGeAlD
Crizotinib—SRC—connective tissue—glaucoma	0.000485	0.00843	CbGeAlD
Crizotinib—ABCB1—Clonidine—glaucoma	0.000471	0.112	CbGbCtD
Crizotinib—CYP3A4—Brinzolamide—glaucoma	0.000453	0.108	CbGbCtD
Crizotinib—CSF1R—eye—glaucoma	0.000452	0.00785	CbGeAlD
Crizotinib—CYP3A4—Dorzolamide—glaucoma	0.000438	0.104	CbGbCtD
Crizotinib—CSF1R—connective tissue—glaucoma	0.000436	0.00756	CbGeAlD
Crizotinib—CYP3A4—Methazolamide—glaucoma	0.00039	0.0929	CbGbCtD
Crizotinib—ABL1—eye—glaucoma	0.000358	0.00621	CbGeAlD
Crizotinib—ABL1—retina—glaucoma	0.000354	0.00615	CbGeAlD
Crizotinib—ABL1—connective tissue—glaucoma	0.000344	0.00598	CbGeAlD
Crizotinib—CYP3A4—Acetazolamide—glaucoma	0.000312	0.0743	CbGbCtD
Crizotinib—CYP3A4—Clonidine—glaucoma	0.000282	0.0672	CbGbCtD
Crizotinib—Skin disorder—Bimatoprost—glaucoma	0.000236	0.00166	CcSEcCtD
Crizotinib—Diarrhoea—Carbachol—glaucoma	0.000235	0.00165	CcSEcCtD
Crizotinib—Vision blurred—Brinzolamide—glaucoma	0.000234	0.00164	CcSEcCtD
Crizotinib—Dysgeusia—Pilocarpine—glaucoma	0.000233	0.00164	CcSEcCtD
Crizotinib—Dizziness—Diclofenamide—glaucoma	0.000233	0.00163	CcSEcCtD
Crizotinib—Asthenia—Methazolamide—glaucoma	0.000233	0.00163	CcSEcCtD
Crizotinib—Loss of consciousness—Brimonidine—glaucoma	0.000232	0.00163	CcSEcCtD
Crizotinib—Diarrhoea—Levobunolol—glaucoma	0.000232	0.00162	CcSEcCtD
Crizotinib—Nausea—Metipranolol—glaucoma	0.00023	0.00161	CcSEcCtD
Crizotinib—Dizziness—Carbachol—glaucoma	0.000227	0.00159	CcSEcCtD
Crizotinib—Syncope—Dorzolamide—glaucoma	0.000226	0.00159	CcSEcCtD
Crizotinib—Paraesthesia—Apraclonidine—glaucoma	0.000225	0.00158	CcSEcCtD
Crizotinib—Diplopia—Timolol—glaucoma	0.000225	0.00158	CcSEcCtD
Crizotinib—Vision blurred—Pilocarpine—glaucoma	0.000225	0.00157	CcSEcCtD
Crizotinib—Vomiting—Diclofenamide—glaucoma	0.000224	0.00157	CcSEcCtD
Crizotinib—Dizziness—Levobunolol—glaucoma	0.000224	0.00157	CcSEcCtD
Crizotinib—Dyspnoea—Apraclonidine—glaucoma	0.000224	0.00157	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000223	0.00156	CcSEcCtD
Crizotinib—Bradycardia—Clonidine—glaucoma	0.000223	0.00156	CcSEcCtD
Crizotinib—Rash—Diclofenamide—glaucoma	0.000222	0.00156	CcSEcCtD
Crizotinib—Diarrhoea—Methazolamide—glaucoma	0.000222	0.00156	CcSEcCtD
Crizotinib—Loss of consciousness—Dorzolamide—glaucoma	0.000222	0.00155	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Betaxolol—glaucoma	0.000221	0.00155	CcSEcCtD
Crizotinib—Shock—Acetazolamide—glaucoma	0.000221	0.00155	CcSEcCtD
Crizotinib—Vomiting—Carbachol—glaucoma	0.000219	0.00153	CcSEcCtD
Crizotinib—Hypoaesthesia—Clonidine—glaucoma	0.000218	0.00152	CcSEcCtD
Crizotinib—Dyspnoea—Bimatoprost—glaucoma	0.000217	0.00152	CcSEcCtD
Crizotinib—Rash—Carbachol—glaucoma	0.000217	0.00152	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000217	0.00152	CcSEcCtD
Crizotinib—Dermatitis—Carbachol—glaucoma	0.000217	0.00152	CcSEcCtD
Crizotinib—Fatigue—Apraclonidine—glaucoma	0.000216	0.00152	CcSEcCtD
Crizotinib—Oedema—Brimonidine—glaucoma	0.000216	0.00151	CcSEcCtD
Crizotinib—Weight decreased—Betaxolol—glaucoma	0.000215	0.00151	CcSEcCtD
Crizotinib—Constipation—Apraclonidine—glaucoma	0.000215	0.0015	CcSEcCtD
Crizotinib—Dyspepsia—Bimatoprost—glaucoma	0.000214	0.0015	CcSEcCtD
Crizotinib—Infection—Brimonidine—glaucoma	0.000214	0.0015	CcSEcCtD
Crizotinib—Syncope—Pilocarpine—glaucoma	0.000214	0.0015	CcSEcCtD
Crizotinib—Leukopenia—Pilocarpine—glaucoma	0.000213	0.0015	CcSEcCtD
Crizotinib—Pneumonia—Betaxolol—glaucoma	0.000213	0.00149	CcSEcCtD
Crizotinib—Nausea—Carteolol—glaucoma	0.000213	0.00149	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000212	0.00149	CcSEcCtD
Crizotinib—Shock—Brimonidine—glaucoma	0.000212	0.00149	CcSEcCtD
Crizotinib—Infestation NOS—Betaxolol—glaucoma	0.000212	0.00149	CcSEcCtD
Crizotinib—Infestation—Betaxolol—glaucoma	0.000212	0.00149	CcSEcCtD
Crizotinib—Nervous system disorder—Brimonidine—glaucoma	0.000211	0.00148	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00021	0.00147	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00021	0.00147	CcSEcCtD
Crizotinib—Loss of consciousness—Pilocarpine—glaucoma	0.000209	0.00147	CcSEcCtD
Crizotinib—Skin disorder—Brimonidine—glaucoma	0.000209	0.00147	CcSEcCtD
Crizotinib—Nausea—Diclofenamide—glaucoma	0.000209	0.00147	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betaxolol—glaucoma	0.000208	0.00146	CcSEcCtD
Crizotinib—Dizziness—Latanoprost—glaucoma	0.000208	0.00146	CcSEcCtD
Crizotinib—Vomiting—Methazolamide—glaucoma	0.000206	0.00145	CcSEcCtD
Crizotinib—Oedema—Dorzolamide—glaucoma	0.000206	0.00144	CcSEcCtD
Crizotinib—Oedema—Travoprost—glaucoma	0.000205	0.00144	CcSEcCtD
Crizotinib—Rash—Methazolamide—glaucoma	0.000205	0.00143	CcSEcCtD
Crizotinib—Dermatitis—Methazolamide—glaucoma	0.000204	0.00143	CcSEcCtD
Crizotinib—Eye disorder—Clonidine—glaucoma	0.000204	0.00143	CcSEcCtD
Crizotinib—Nausea—Carbachol—glaucoma	0.000204	0.00143	CcSEcCtD
Crizotinib—Infection—Travoprost—glaucoma	0.000204	0.00143	CcSEcCtD
Crizotinib—Cardiac disorder—Clonidine—glaucoma	0.000203	0.00142	CcSEcCtD
Crizotinib—Shock—Dorzolamide—glaucoma	0.000203	0.00142	CcSEcCtD
Crizotinib—Paraesthesia—Acetazolamide—glaucoma	0.000202	0.00141	CcSEcCtD
Crizotinib—Nausea—Levobunolol—glaucoma	0.000201	0.00141	CcSEcCtD
Crizotinib—Infection—Brinzolamide—glaucoma	0.000201	0.00141	CcSEcCtD
Crizotinib—Nervous system disorder—Travoprost—glaucoma	0.000201	0.00141	CcSEcCtD
Crizotinib—Skin disorder—Travoprost—glaucoma	0.000199	0.0014	CcSEcCtD
Crizotinib—Nervous system disorder—Brinzolamide—glaucoma	0.000198	0.00139	CcSEcCtD
Crizotinib—Rash—Latanoprost—glaucoma	0.000198	0.00139	CcSEcCtD
Crizotinib—Dermatitis—Latanoprost—glaucoma	0.000198	0.00139	CcSEcCtD
Crizotinib—Dyspepsia—Acetazolamide—glaucoma	0.000198	0.00139	CcSEcCtD
Crizotinib—Mediastinal disorder—Clonidine—glaucoma	0.000197	0.00138	CcSEcCtD
Crizotinib—Skin disorder—Brinzolamide—glaucoma	0.000197	0.00138	CcSEcCtD
Crizotinib—Arrhythmia—Clonidine—glaucoma	0.000195	0.00137	CcSEcCtD
Crizotinib—Decreased appetite—Acetazolamide—glaucoma	0.000195	0.00137	CcSEcCtD
Crizotinib—Oedema—Pilocarpine—glaucoma	0.000194	0.00136	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000194	0.00136	CcSEcCtD
Crizotinib—Bradycardia—Betaxolol—glaucoma	0.000194	0.00136	CcSEcCtD
Crizotinib—Fatigue—Acetazolamide—glaucoma	0.000194	0.00136	CcSEcCtD
Crizotinib—Paraesthesia—Brimonidine—glaucoma	0.000194	0.00136	CcSEcCtD
Crizotinib—Infection—Pilocarpine—glaucoma	0.000193	0.00135	CcSEcCtD
Crizotinib—Nausea—Methazolamide—glaucoma	0.000193	0.00135	CcSEcCtD
Crizotinib—Dyspnoea—Brimonidine—glaucoma	0.000192	0.00135	CcSEcCtD
Crizotinib—Shock—Pilocarpine—glaucoma	0.000191	0.00134	CcSEcCtD
Crizotinib—Dyspepsia—Brimonidine—glaucoma	0.00019	0.00133	CcSEcCtD
Crizotinib—Hypoaesthesia—Betaxolol—glaucoma	0.000189	0.00133	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000186	0.0013	CcSEcCtD
Crizotinib—Fatigue—Brimonidine—glaucoma	0.000186	0.0013	CcSEcCtD
Crizotinib—Paraesthesia—Dorzolamide—glaucoma	0.000185	0.0013	CcSEcCtD
Crizotinib—Dyspnoea—Dorzolamide—glaucoma	0.000184	0.00129	CcSEcCtD
Crizotinib—Visual impairment—Betaxolol—glaucoma	0.000183	0.00129	CcSEcCtD
Crizotinib—Dyspnoea—Travoprost—glaucoma	0.000183	0.00128	CcSEcCtD
Crizotinib—Paraesthesia—Brinzolamide—glaucoma	0.000182	0.00127	CcSEcCtD
Crizotinib—Dyspepsia—Dorzolamide—glaucoma	0.000181	0.00127	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Timolol—glaucoma	0.000181	0.00127	CcSEcCtD
Crizotinib—Dyspnoea—Brinzolamide—glaucoma	0.00018	0.00126	CcSEcCtD
Crizotinib—Dyspepsia—Travoprost—glaucoma	0.00018	0.00126	CcSEcCtD
Crizotinib—Asthenia—Apraclonidine—glaucoma	0.00018	0.00126	CcSEcCtD
Crizotinib—Vision blurred—Clonidine—glaucoma	0.000179	0.00126	CcSEcCtD
Crizotinib—Decreased appetite—Dorzolamide—glaucoma	0.000179	0.00125	CcSEcCtD
Crizotinib—Dyspepsia—Brinzolamide—glaucoma	0.000178	0.00125	CcSEcCtD
Crizotinib—Eye disorder—Betaxolol—glaucoma	0.000178	0.00125	CcSEcCtD
Crizotinib—Body temperature increased—Acetazolamide—glaucoma	0.000178	0.00124	CcSEcCtD
Crizotinib—Fatigue—Dorzolamide—glaucoma	0.000177	0.00124	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Travoprost—glaucoma	0.000177	0.00124	CcSEcCtD
Crizotinib—Fatigue—Travoprost—glaucoma	0.000177	0.00124	CcSEcCtD
Crizotinib—Cardiac disorder—Betaxolol—glaucoma	0.000177	0.00124	CcSEcCtD
Crizotinib—Decreased appetite—Brinzolamide—glaucoma	0.000176	0.00123	CcSEcCtD
Crizotinib—Weight decreased—Timolol—glaucoma	0.000176	0.00123	CcSEcCtD
Crizotinib—Constipation—Travoprost—glaucoma	0.000175	0.00123	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000175	0.00122	CcSEcCtD
Crizotinib—Paraesthesia—Pilocarpine—glaucoma	0.000175	0.00122	CcSEcCtD
Crizotinib—Asthenia—Bimatoprost—glaucoma	0.000175	0.00122	CcSEcCtD
Crizotinib—Fatigue—Brinzolamide—glaucoma	0.000174	0.00122	CcSEcCtD
Crizotinib—Dyspnoea—Pilocarpine—glaucoma	0.000173	0.00122	CcSEcCtD
Crizotinib—Diarrhoea—Apraclonidine—glaucoma	0.000172	0.0012	CcSEcCtD
Crizotinib—Mediastinal disorder—Betaxolol—glaucoma	0.000172	0.0012	CcSEcCtD
Crizotinib—Dyspepsia—Pilocarpine—glaucoma	0.000171	0.0012	CcSEcCtD
Crizotinib—Syncope—Clonidine—glaucoma	0.000171	0.0012	CcSEcCtD
Crizotinib—Arrhythmia—Betaxolol—glaucoma	0.00017	0.00119	CcSEcCtD
Crizotinib—Decreased appetite—Pilocarpine—glaucoma	0.000169	0.00118	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000168	0.00118	CcSEcCtD
Crizotinib—Loss of consciousness—Clonidine—glaucoma	0.000167	0.00117	CcSEcCtD
Crizotinib—Constipation—Pilocarpine—glaucoma	0.000166	0.00117	CcSEcCtD
Crizotinib—Dizziness—Apraclonidine—glaucoma	0.000166	0.00116	CcSEcCtD
Crizotinib—Malnutrition—Betaxolol—glaucoma	0.000166	0.00116	CcSEcCtD
Crizotinib—Body temperature increased—Dorzolamide—glaucoma	0.000163	0.00114	CcSEcCtD
Crizotinib—Dysgeusia—Betaxolol—glaucoma	0.000162	0.00114	CcSEcCtD
Crizotinib—Asthenia—Acetazolamide—glaucoma	0.000161	0.00113	CcSEcCtD
Crizotinib—Dizziness—Bimatoprost—glaucoma	0.000161	0.00113	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000161	0.00113	CcSEcCtD
Crizotinib—Vomiting—Apraclonidine—glaucoma	0.00016	0.00112	CcSEcCtD
Crizotinib—Bradycardia—Timolol—glaucoma	0.000158	0.00111	CcSEcCtD
Crizotinib—Dermatitis—Apraclonidine—glaucoma	0.000158	0.00111	CcSEcCtD
Crizotinib—Vision blurred—Betaxolol—glaucoma	0.000156	0.00109	CcSEcCtD
Crizotinib—Oedema—Clonidine—glaucoma	0.000155	0.00109	CcSEcCtD
Crizotinib—Asthenia—Brimonidine—glaucoma	0.000155	0.00108	CcSEcCtD
Crizotinib—Infection—Clonidine—glaucoma	0.000154	0.00108	CcSEcCtD
Crizotinib—Body temperature increased—Pilocarpine—glaucoma	0.000154	0.00108	CcSEcCtD
Crizotinib—Diarrhoea—Acetazolamide—glaucoma	0.000154	0.00108	CcSEcCtD
Crizotinib—Rash—Bimatoprost—glaucoma	0.000153	0.00108	CcSEcCtD
Crizotinib—Dermatitis—Bimatoprost—glaucoma	0.000153	0.00107	CcSEcCtD
Crizotinib—Oedema peripheral—Timolol—glaucoma	0.000153	0.00107	CcSEcCtD
Crizotinib—Anaemia—Betaxolol—glaucoma	0.000153	0.00107	CcSEcCtD
Crizotinib—Shock—Clonidine—glaucoma	0.000153	0.00107	CcSEcCtD
Crizotinib—Nervous system disorder—Clonidine—glaucoma	0.000152	0.00107	CcSEcCtD
Crizotinib—Skin disorder—Clonidine—glaucoma	0.000151	0.00106	CcSEcCtD
Crizotinib—Visual impairment—Timolol—glaucoma	0.00015	0.00105	CcSEcCtD
Crizotinib—Nausea—Apraclonidine—glaucoma	0.000149	0.00105	CcSEcCtD
Crizotinib—Syncope—Betaxolol—glaucoma	0.000149	0.00104	CcSEcCtD
Crizotinib—Dizziness—Acetazolamide—glaucoma	0.000149	0.00104	CcSEcCtD
Crizotinib—Asthenia—Dorzolamide—glaucoma	0.000148	0.00104	CcSEcCtD
Crizotinib—Asthenia—Travoprost—glaucoma	0.000147	0.00103	CcSEcCtD
Crizotinib—Loss of consciousness—Betaxolol—glaucoma	0.000146	0.00102	CcSEcCtD
Crizotinib—Eye disorder—Timolol—glaucoma	0.000145	0.00102	CcSEcCtD
Crizotinib—Asthenia—Brinzolamide—glaucoma	0.000145	0.00102	CcSEcCtD
Crizotinib—Nausea—Bimatoprost—glaucoma	0.000145	0.00101	CcSEcCtD
Crizotinib—Cardiac disorder—Timolol—glaucoma	0.000144	0.00101	CcSEcCtD
Crizotinib—Vomiting—Acetazolamide—glaucoma	0.000143	0.001	CcSEcCtD
Crizotinib—Dizziness—Brimonidine—glaucoma	0.000143	0.000999	CcSEcCtD
Crizotinib—Diarrhoea—Dorzolamide—glaucoma	0.000141	0.000987	CcSEcCtD
Crizotinib—Diarrhoea—Travoprost—glaucoma	0.00014	0.000983	CcSEcCtD
Crizotinib—Mediastinal disorder—Timolol—glaucoma	0.00014	0.000982	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.00014	0.000982	CcSEcCtD
Crizotinib—Asthenia—Pilocarpine—glaucoma	0.00014	0.000978	CcSEcCtD
Crizotinib—Paraesthesia—Clonidine—glaucoma	0.000139	0.000977	CcSEcCtD
Crizotinib—Arrhythmia—Timolol—glaucoma	0.000139	0.000973	CcSEcCtD
Crizotinib—Dyspnoea—Clonidine—glaucoma	0.000138	0.00097	CcSEcCtD
Crizotinib—Diarrhoea—Brinzolamide—glaucoma	0.000138	0.00097	CcSEcCtD
Crizotinib—Dizziness—Dorzolamide—glaucoma	0.000136	0.000954	CcSEcCtD
Crizotinib—Rash—Brimonidine—glaucoma	0.000136	0.000952	CcSEcCtD
Crizotinib—Dermatitis—Brimonidine—glaucoma	0.000136	0.000952	CcSEcCtD
Crizotinib—Dizziness—Travoprost—glaucoma	0.000136	0.00095	CcSEcCtD
Crizotinib—Malnutrition—Timolol—glaucoma	0.000135	0.000949	CcSEcCtD
Crizotinib—Oedema—Betaxolol—glaucoma	0.000135	0.000948	CcSEcCtD
Crizotinib—Decreased appetite—Clonidine—glaucoma	0.000135	0.000946	CcSEcCtD
Crizotinib—Infection—Betaxolol—glaucoma	0.000134	0.000941	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000134	0.00094	CcSEcCtD
Crizotinib—Fatigue—Clonidine—glaucoma	0.000134	0.000938	CcSEcCtD
Crizotinib—Dizziness—Brinzolamide—glaucoma	0.000134	0.000938	CcSEcCtD
Crizotinib—Nausea—Acetazolamide—glaucoma	0.000133	0.000935	CcSEcCtD
Crizotinib—Diarrhoea—Pilocarpine—glaucoma	0.000133	0.000933	CcSEcCtD
Crizotinib—Shock—Betaxolol—glaucoma	0.000133	0.000932	CcSEcCtD
Crizotinib—Constipation—Clonidine—glaucoma	0.000133	0.000931	CcSEcCtD
Crizotinib—Nervous system disorder—Betaxolol—glaucoma	0.000133	0.000929	CcSEcCtD
Crizotinib—Dysgeusia—Timolol—glaucoma	0.000133	0.000929	CcSEcCtD
Crizotinib—Skin disorder—Betaxolol—glaucoma	0.000131	0.000921	CcSEcCtD
Crizotinib—Vomiting—Dorzolamide—glaucoma	0.000131	0.000917	CcSEcCtD
Crizotinib—Rash—Dorzolamide—glaucoma	0.00013	0.00091	CcSEcCtD
Crizotinib—Dermatitis—Dorzolamide—glaucoma	0.00013	0.000909	CcSEcCtD
Crizotinib—Rash—Travoprost—glaucoma	0.000129	0.000906	CcSEcCtD
Crizotinib—Dermatitis—Travoprost—glaucoma	0.000129	0.000905	CcSEcCtD
Crizotinib—Vomiting—Brinzolamide—glaucoma	0.000129	0.000902	CcSEcCtD
Crizotinib—Dizziness—Pilocarpine—glaucoma	0.000129	0.000901	CcSEcCtD
Crizotinib—Nausea—Brimonidine—glaucoma	0.000128	0.000897	CcSEcCtD
Crizotinib—Rash—Brinzolamide—glaucoma	0.000128	0.000894	CcSEcCtD
Crizotinib—Vision blurred—Timolol—glaucoma	0.000128	0.000894	CcSEcCtD
Crizotinib—Dermatitis—Brinzolamide—glaucoma	0.000127	0.000893	CcSEcCtD
Crizotinib—Vomiting—Pilocarpine—glaucoma	0.000124	0.000867	CcSEcCtD
Crizotinib—Body temperature increased—Clonidine—glaucoma	0.000123	0.000861	CcSEcCtD
Crizotinib—Rash—Pilocarpine—glaucoma	0.000123	0.000859	CcSEcCtD
Crizotinib—Dermatitis—Pilocarpine—glaucoma	0.000123	0.000859	CcSEcCtD
Crizotinib—Nausea—Dorzolamide—glaucoma	0.000122	0.000857	CcSEcCtD
Crizotinib—Nausea—Travoprost—glaucoma	0.000122	0.000853	CcSEcCtD
Crizotinib—Paraesthesia—Betaxolol—glaucoma	0.000121	0.000851	CcSEcCtD
Crizotinib—Syncope—Timolol—glaucoma	0.000121	0.000851	CcSEcCtD
Crizotinib—Dyspnoea—Betaxolol—glaucoma	0.000121	0.000845	CcSEcCtD
Crizotinib—Nausea—Brinzolamide—glaucoma	0.00012	0.000842	CcSEcCtD
Crizotinib—Dyspepsia—Betaxolol—glaucoma	0.000119	0.000834	CcSEcCtD
Crizotinib—Loss of consciousness—Timolol—glaucoma	0.000119	0.000834	CcSEcCtD
Crizotinib—Decreased appetite—Betaxolol—glaucoma	0.000118	0.000824	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000117	0.000818	CcSEcCtD
Crizotinib—Fatigue—Betaxolol—glaucoma	0.000117	0.000817	CcSEcCtD
Crizotinib—Constipation—Betaxolol—glaucoma	0.000116	0.00081	CcSEcCtD
Crizotinib—Nausea—Pilocarpine—glaucoma	0.000116	0.00081	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000114	0.000802	CcSEcCtD
Crizotinib—Asthenia—Clonidine—glaucoma	0.000111	0.000781	CcSEcCtD
Crizotinib—Oedema—Timolol—glaucoma	0.00011	0.000774	CcSEcCtD
Crizotinib—ABCB1—retina—glaucoma	0.00011	0.00191	CbGeAlD
Crizotinib—Infection—Timolol—glaucoma	0.00011	0.000769	CcSEcCtD
Crizotinib—Shock—Timolol—glaucoma	0.000109	0.000762	CcSEcCtD
Crizotinib—Nervous system disorder—Timolol—glaucoma	0.000108	0.000759	CcSEcCtD
Crizotinib—Skin disorder—Timolol—glaucoma	0.000107	0.000752	CcSEcCtD
Crizotinib—Body temperature increased—Betaxolol—glaucoma	0.000107	0.000749	CcSEcCtD
Crizotinib—Diarrhoea—Clonidine—glaucoma	0.000106	0.000745	CcSEcCtD
Crizotinib—Dizziness—Clonidine—glaucoma	0.000103	0.00072	CcSEcCtD
Crizotinib—Paraesthesia—Timolol—glaucoma	9.92e-05	0.000695	CcSEcCtD
Crizotinib—Vomiting—Clonidine—glaucoma	9.88e-05	0.000692	CcSEcCtD
Crizotinib—Dyspnoea—Timolol—glaucoma	9.85e-05	0.00069	CcSEcCtD
Crizotinib—Rash—Clonidine—glaucoma	9.79e-05	0.000686	CcSEcCtD
Crizotinib—Dermatitis—Clonidine—glaucoma	9.78e-05	0.000686	CcSEcCtD
Crizotinib—Dyspepsia—Timolol—glaucoma	9.72e-05	0.000681	CcSEcCtD
Crizotinib—Asthenia—Betaxolol—glaucoma	9.7e-05	0.00068	CcSEcCtD
Crizotinib—Decreased appetite—Timolol—glaucoma	9.6e-05	0.000673	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Timolol—glaucoma	9.54e-05	0.000668	CcSEcCtD
Crizotinib—Fatigue—Timolol—glaucoma	9.52e-05	0.000667	CcSEcCtD
Crizotinib—Diarrhoea—Betaxolol—glaucoma	9.25e-05	0.000648	CcSEcCtD
Crizotinib—Nausea—Clonidine—glaucoma	9.23e-05	0.000647	CcSEcCtD
Crizotinib—Dizziness—Betaxolol—glaucoma	8.94e-05	0.000627	CcSEcCtD
Crizotinib—Body temperature increased—Timolol—glaucoma	8.73e-05	0.000612	CcSEcCtD
Crizotinib—Vomiting—Betaxolol—glaucoma	8.6e-05	0.000603	CcSEcCtD
Crizotinib—Rash—Betaxolol—glaucoma	8.53e-05	0.000598	CcSEcCtD
Crizotinib—Dermatitis—Betaxolol—glaucoma	8.52e-05	0.000597	CcSEcCtD
Crizotinib—Nausea—Betaxolol—glaucoma	8.03e-05	0.000563	CcSEcCtD
Crizotinib—Asthenia—Timolol—glaucoma	7.93e-05	0.000555	CcSEcCtD
Crizotinib—Diarrhoea—Timolol—glaucoma	7.56e-05	0.00053	CcSEcCtD
Crizotinib—Dizziness—Timolol—glaucoma	7.31e-05	0.000512	CcSEcCtD
Crizotinib—Vomiting—Timolol—glaucoma	7.02e-05	0.000492	CcSEcCtD
Crizotinib—Rash—Timolol—glaucoma	6.97e-05	0.000488	CcSEcCtD
Crizotinib—Dermatitis—Timolol—glaucoma	6.96e-05	0.000488	CcSEcCtD
Crizotinib—Nausea—Timolol—glaucoma	6.56e-05	0.00046	CcSEcCtD
Crizotinib—MAPK7—Signaling Pathways—MMP9—glaucoma	3.31e-06	2.03e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CAV1—glaucoma	3.29e-06	2.02e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EDN1—glaucoma	3.27e-06	2.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—C3—glaucoma	3.25e-06	2e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1A—glaucoma	3.24e-06	1.99e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FN1—glaucoma	3.23e-06	1.98e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NGF—glaucoma	3.22e-06	1.98e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SMO—glaucoma	3.2e-06	1.97e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—BAD—glaucoma	3.19e-06	1.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—VEGFA—glaucoma	3.18e-06	1.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EDN1—glaucoma	3.18e-06	1.95e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—glaucoma	3.18e-06	1.95e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NGF—glaucoma	3.17e-06	1.95e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN2B—glaucoma	3.14e-06	1.93e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FN1—glaucoma	3.13e-06	1.92e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	3.12e-06	1.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—VEGFA—glaucoma	3.12e-06	1.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BCL2L1—glaucoma	3.12e-06	1.91e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—BAD—glaucoma	3.09e-06	1.9e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NGFR—glaucoma	3.06e-06	1.88e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—C3—glaucoma	3.06e-06	1.88e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NOS3—glaucoma	3.05e-06	1.87e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—VEGFA—glaucoma	3.04e-06	1.87e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—BAD—glaucoma	3.02e-06	1.85e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—C3—glaucoma	3.02e-06	1.85e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NGF—glaucoma	3.01e-06	1.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTHFR—glaucoma	3e-06	1.85e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—BAD—glaucoma	3e-06	1.85e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—VEGFA—glaucoma	2.97e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CDKN1B—glaucoma	2.96e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NTRK2—glaucoma	2.93e-06	1.8e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NGF—glaucoma	2.92e-06	1.79e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—glaucoma	2.91e-06	1.79e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NTRK1—glaucoma	2.91e-06	1.79e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—glaucoma	2.9e-06	1.78e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—glaucoma	2.9e-06	1.78e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1A—glaucoma	2.87e-06	1.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NGFR—glaucoma	2.87e-06	1.76e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—C3—glaucoma	2.86e-06	1.76e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CDKN1B—glaucoma	2.86e-06	1.76e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—C3—glaucoma	2.85e-06	1.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—APOE—glaucoma	2.85e-06	1.75e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CDKN1B—glaucoma	2.84e-06	1.74e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SMO—glaucoma	2.83e-06	1.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BAD—glaucoma	2.82e-06	1.73e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CAV1—glaucoma	2.82e-06	1.73e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CDKN1B—glaucoma	2.82e-06	1.73e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—APOE—glaucoma	2.81e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—APOE—glaucoma	2.8e-06	1.72e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CAV1—glaucoma	2.78e-06	1.71e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN2B—glaucoma	2.78e-06	1.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—C3—glaucoma	2.78e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CAV1—glaucoma	2.77e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS3—glaucoma	2.77e-06	1.7e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP9—glaucoma	2.74e-06	1.69e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—VEGFA—glaucoma	2.73e-06	1.68e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL2L1—glaucoma	2.73e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—glaucoma	2.72e-06	1.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NTRK1—glaucoma	2.72e-06	1.67e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NOS3—glaucoma	2.72e-06	1.67e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTT1—glaucoma	2.72e-06	1.67e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FN1—glaucoma	2.68e-06	1.65e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN2B—glaucoma	2.68e-06	1.65e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NOS3—glaucoma	2.68e-06	1.65e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.67e-06	1.64e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CDKN1B—glaucoma	2.67e-06	1.64e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—APOE—glaucoma	2.66e-06	1.64e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—BAD—glaucoma	2.65e-06	1.63e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FN1—glaucoma	2.65e-06	1.63e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TXN—glaucoma	2.64e-06	1.63e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CDKN1B—glaucoma	2.64e-06	1.62e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CAV1—glaucoma	2.64e-06	1.62e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—glaucoma	2.63e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CDKN1B—glaucoma	2.62e-06	1.61e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—BAD—glaucoma	2.62e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—BAD—glaucoma	2.61e-06	1.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CDKN1B—glaucoma	2.59e-06	1.59e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NTRK2—glaucoma	2.59e-06	1.59e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APOE—glaucoma	2.58e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EDN1—glaucoma	2.57e-06	1.58e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NOS3—glaucoma	2.56e-06	1.58e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CAV1—glaucoma	2.56e-06	1.57e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—glaucoma	2.54e-06	1.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTGS2—glaucoma	2.53e-06	1.55e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CA1—glaucoma	2.53e-06	1.55e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—C3—glaucoma	2.52e-06	1.55e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—glaucoma	2.52e-06	1.55e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CDKN1B—glaucoma	2.51e-06	1.54e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGFR—glaucoma	2.51e-06	1.54e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FN1—glaucoma	2.51e-06	1.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN2B—glaucoma	2.51e-06	1.54e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—glaucoma	2.51e-06	1.54e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NOS3—glaucoma	2.49e-06	1.53e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—BAD—glaucoma	2.48e-06	1.52e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—BAD—glaucoma	2.47e-06	1.52e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—glaucoma	2.46e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APOE—glaucoma	2.45e-06	1.51e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTSA—glaucoma	2.45e-06	1.5e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—glaucoma	2.45e-06	1.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FN1—glaucoma	2.44e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CAV1—glaucoma	2.43e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—glaucoma	2.42e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2L1—glaucoma	2.42e-06	1.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—BAD—glaucoma	2.41e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDN1—glaucoma	2.41e-06	1.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CDKN1B—glaucoma	2.4e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NTRK1—glaucoma	2.39e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NGF—glaucoma	2.37e-06	1.45e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.36e-06	1.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—glaucoma	2.36e-06	1.45e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CDKN1B—glaucoma	2.35e-06	1.45e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—glaucoma	2.33e-06	1.43e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CDKN1B—glaucoma	2.32e-06	1.43e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CA2—glaucoma	2.31e-06	1.42e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—glaucoma	2.3e-06	1.41e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—BAD—glaucoma	2.28e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—C3—glaucoma	2.25e-06	1.38e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—glaucoma	2.25e-06	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGFR—glaucoma	2.22e-06	1.37e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CDKN1B—glaucoma	2.22e-06	1.36e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NGF—glaucoma	2.21e-06	1.36e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN2B—glaucoma	2.2e-06	1.35e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—glaucoma	2.2e-06	1.35e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—BAD—glaucoma	2.19e-06	1.35e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—glaucoma	2.18e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—glaucoma	2.17e-06	1.33e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCA1—glaucoma	2.17e-06	1.33e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP1B1—glaucoma	2.17e-06	1.33e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1B—glaucoma	2.15e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CAV1—glaucoma	2.15e-06	1.32e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—glaucoma	2.15e-06	1.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—glaucoma	2.13e-06	1.31e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—glaucoma	2.11e-06	1.3e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NTRK1—glaucoma	2.11e-06	1.3e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDN1—glaucoma	2.11e-06	1.3e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—C3—glaucoma	2.1e-06	1.29e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—glaucoma	2.1e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1B—glaucoma	2.1e-06	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—glaucoma	2.1e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—glaucoma	2.09e-06	1.29e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1B—glaucoma	2.09e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CAV1—glaucoma	2.07e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—glaucoma	2.06e-06	1.27e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—glaucoma	2.06e-06	1.26e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTT1—glaucoma	2.05e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—BAD—glaucoma	2.02e-06	1.24e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—glaucoma	1.99e-06	1.23e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—glaucoma	1.99e-06	1.23e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FN1—glaucoma	1.97e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1B—glaucoma	1.97e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—glaucoma	1.96e-06	1.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—glaucoma	1.96e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—BAD—glaucoma	1.95e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN2B—glaucoma	1.95e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CAV1—glaucoma	1.94e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGF—glaucoma	1.94e-06	1.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—glaucoma	1.94e-06	1.19e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—glaucoma	1.93e-06	1.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—glaucoma	1.92e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDN1—glaucoma	1.87e-06	1.15e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1B—glaucoma	1.85e-06	1.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FN1—glaucoma	1.85e-06	1.14e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—glaucoma	1.85e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C3—glaucoma	1.84e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—glaucoma	1.84e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—glaucoma	1.83e-06	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BAD—glaucoma	1.83e-06	1.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1B—glaucoma	1.82e-06	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1B—glaucoma	1.82e-06	1.12e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—glaucoma	1.79e-06	1.1e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTM1—glaucoma	1.73e-06	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1B—glaucoma	1.73e-06	1.06e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1B—glaucoma	1.72e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGF—glaucoma	1.72e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—glaucoma	1.72e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—glaucoma	1.71e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CAV1—glaucoma	1.7e-06	1.04e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—glaucoma	1.69e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—glaucoma	1.68e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1B—glaucoma	1.68e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—glaucoma	1.66e-06	1.02e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1B1—glaucoma	1.63e-06	1e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ABCA1—glaucoma	1.63e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C3—glaucoma	1.63e-06	1e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TXN—glaucoma	1.63e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—glaucoma	1.62e-06	9.98e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FN1—glaucoma	1.62e-06	9.94e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—glaucoma	1.6e-06	9.83e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BAD—glaucoma	1.6e-06	9.82e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1B—glaucoma	1.59e-06	9.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—glaucoma	1.57e-06	9.64e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—glaucoma	1.55e-06	9.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—glaucoma	1.54e-06	9.44e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—glaucoma	1.53e-06	9.4e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1B—glaucoma	1.52e-06	9.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—glaucoma	1.52e-06	9.33e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—glaucoma	1.52e-06	9.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CAV1—glaucoma	1.5e-06	9.25e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—glaucoma	1.49e-06	9.13e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—glaucoma	1.48e-06	9.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—glaucoma	1.47e-06	9.02e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—glaucoma	1.46e-06	8.96e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—glaucoma	1.44e-06	8.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FN1—glaucoma	1.43e-06	8.8e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—glaucoma	1.42e-06	8.75e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BAD—glaucoma	1.42e-06	8.7e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAV1—glaucoma	1.41e-06	8.67e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—glaucoma	1.41e-06	8.65e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—glaucoma	1.4e-06	8.57e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—glaucoma	1.39e-06	8.57e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—glaucoma	1.36e-06	8.35e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—glaucoma	1.35e-06	8.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—glaucoma	1.31e-06	8.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—glaucoma	1.29e-06	7.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—glaucoma	1.27e-06	7.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—glaucoma	1.26e-06	7.76e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—glaucoma	1.26e-06	7.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—glaucoma	1.18e-06	7.23e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—glaucoma	1.16e-06	7.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—glaucoma	1.15e-06	7.09e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—glaucoma	1.14e-06	7.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—glaucoma	1.14e-06	6.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—glaucoma	1.13e-06	6.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—glaucoma	1.11e-06	6.84e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—glaucoma	1.09e-06	6.67e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—glaucoma	1.07e-06	6.6e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—glaucoma	1.07e-06	6.56e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—glaucoma	1.06e-06	6.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—glaucoma	1.06e-06	6.5e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—glaucoma	1.05e-06	6.48e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—glaucoma	1.03e-06	6.34e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—glaucoma	1.01e-06	6.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCA1—glaucoma	1.01e-06	6.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—glaucoma	9.86e-07	6.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—glaucoma	9.76e-07	6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—glaucoma	9.26e-07	5.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—glaucoma	9.13e-07	5.61e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—glaucoma	8.54e-07	5.25e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—glaucoma	8.2e-07	5.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—glaucoma	8.05e-07	4.95e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—glaucoma	8.05e-07	4.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—glaucoma	7.99e-07	4.91e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—glaucoma	7.36e-07	4.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—glaucoma	7.11e-07	4.37e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—glaucoma	7e-07	4.3e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—glaucoma	6.62e-07	4.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—glaucoma	6.56e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—glaucoma	6.19e-07	3.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—glaucoma	4.96e-07	3.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—glaucoma	4.54e-07	2.79e-06	CbGpPWpGaD
